Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518893PMC
http://dx.doi.org/10.3324/haematol.2018.215103DOI Listing

Publication Analysis

Top Keywords

leukemic presentation
4
presentation alk-positive
4
alk-positive anaplastic
4
anaplastic large
4
large cell
4
cell lymphoma
4
lymphoma novel
4
novel partner
4
partner polya
4
polya binding
4

Similar Publications

Background: A patient with acute myeloid leukemia (AML) presented with a cardiac mass of unknown nature. This case underscores the importance of careful monitoring and a multidisciplinary approach in managing and differentiation of rare cardiac complications in leukemia patients. It aims to improve diagnostic accuracy and therapeutic outcomes in similar challenging scenarios.

View Article and Find Full Text PDF

Recurrence of chronic lymphatic leukemia as infiltration of the spinal cord.

J Med Life

November 2024

3rd Medical Department, Hanusch Krankenhaus, Vienna, Austria.

Central nervous system (CNS) involvement in chronic lymphocytic leukemia (CLL) is rare, and spinal cord infiltration as a presenting manifestation has only rarely been described. We present the case of a 65-year-old man with CLL, initially diagnosed at the age of 54, who had not received prior treatment. He presented with a six-week history of thoracic and epigastric pressure.

View Article and Find Full Text PDF

There is a high medical need to develop new strategies for the treatment of patients with acute myeloid leukemia (AML) refractory to conventional therapy. In vitro, the combinations of the blast-modulatory response modifiers GM-CSF + Prostaglandin E1, (summarized as Kit M) have been shown to convert myeloid leukemic blasts into antigen-presenting dendritic cells of leukemic origin (DC) that were able to (re-)activate the innate and adaptive immune system, direct it specifically against leukemic blasts, and induce memory cells. This study aimed to investigate the immune modulatory capacity and antileukemic efficacy of Kit M in vivo.

View Article and Find Full Text PDF

[Acquisition of Primary Ph Bone Marrow Cells and Establishment of Ph B-ALL Mouse Model].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Blood Disease Institute, Xuzhou Medical University,Xuzhou 221000, Jiangsu Province, China.

Article Synopsis
  • The objective of the study was to harvest primary Philadelphia chromosome-positive (Ph) cells from B-acute lymphoblastic leukemia (B-ALL) and create a B-ALL mouse model.
  • Methods included infecting bone marrow cells from C57BL/6J mice with a retrovirus, followed by the transplantation of transfected cells into irradiated mice, resulting in the establishment of multiple generations of Ph cells.
  • The results showed significant health deterioration in the mice post-transplant, with pathological features such as weight loss and leukemic cell infiltration in the liver, confirming the successful creation of a B-ALL mouse model through progressive passages of Ph cells.
View Article and Find Full Text PDF

ALDH Enzymes and Hematological Diseases: A Scoping Review of Literature.

Discov Med

December 2024

Department of Biological Hematology, Tours University Hospital, 37000 Tours, France.

Aldehyde dehydrogenases (ALDHs) constitute a group of enzymes that catalyze the oxidation of aldehydes to carboxylic acids. The human ALDH superfamily, including 19 different isoenzymes (ALDH1A1, ALDH1A2, ALDH1A3, AHDH1B1, ALDH1L1, ALDH1L2, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH8A1, ALDH9A1, ALDHA16A1, ALDH18A1), displays different key physiological and toxicological functions, with specific tissue expression and substrate specificity. Several studies have established that ALDH are interesting markers for the identification and quantification of human hematopoietic stem cells and cancer stem cells, notably leukemic stem cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!